0
Abstract: Late-Breaking Science |

INITIAL EXPERIENCE WITH A TISSUE ENGINEERING APPROACH TO BRONCHOSCOPIC LUNG VOLUME REDUCTION IN HUMANS WITH EMPHYSEMA FREE TO VIEW

George R. Washko, MD; Lawrence Kenney, MD; Victor Pinto-Plata, MD; Bartolome Celli, MD; John Reilly, MD
Author and Funding Information

Hyde Park, MA


Chest


Chest. 2005;128(4_MeetingAbstracts):496S-b-497S. doi:10.1378/chest.128.4_MeetingAbstracts.496S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Bronchoscopic lung volume reduction (BLVR) using bioactive agents to remodel damaged lung tissue has reduced lung volume in a sheep model of emphysema. This abstract reports preliminary findings using this approach to treat advanced heterogeneous emphysema in humans.

METHODS:  A two-stage study involving 6 subjects was conducted at 2 medical centers to assess safety. Stage 1 subjects received subtherapeutic treatment at 2 subsegmental sites in a single lung. Stage 2 subjects received treatment at 4 subsegmental sites in a single lung. Safety was assessed as the number of serious adverse events associated with treatment in Stage 1 and 2 subjects.

RESULTS:  There were no serious adverse events associated with initial BLVR treatment in either stage of the study. All subjects were discharged from the hospital on post-treatment Day 1. Two-month follow-up in Stage 2 subjects demonstrated improvements in pre- and post-bronchodilator FEV1 (+11% & +6%) and FVC (+20% & +12%), a reduction in RV (10%), improvement in 6 MWD (+35%), and a reduction in MRC dyspnea (3.3 to 2). These trends did not reach statistical significance. Two of the Stage 1 subjects have had subsequent retreatment at 2 sites. There were no early adverse events after retreatment; studies of therapeutic response are pending.

CONCLUSION:  BLVR using tissue remodeling appears to be safe in subjects with advanced emphysema. Suggestion of efficacy after treatment at 4 sites is apparent at 2-month follow-up.

CLINICAL IMPLICATIONS:  Additional follow-up is needed to assess long-term safety and durability of response. These results warrant further cautious clinical trials.

DISCLOSURE:  George Richard Washko MD, None.

Tuesday, November 1, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543